Researchers Identified New Target for Kidney Cancer
A study uncovered a protein that causes resistance to standard kidney cancer treatment.
Updated on Sept. 30, 2026 in Cancer
Scientists have identified the protein NSUN5 as a primary driver of resistance to the cancer drug sunitinib in renal cell carcinoma. This discovery marks a potential breakthrough in enhancing treatment outcomes for patients.
Why it matters
Understanding the mechanism behind drug resistance is critical for developing more effective therapies. Targeting NSUN5 could prevent cancer cells from surviving standard treatments, offering a new pathway for patient care.
NSUN5 expression is elevated in sunitinib-resistant renal cell carcinoma and correlates with poorer patient prognosis. Inhibiting this protein reduces m5C RNA levels and restores sensitivity to treatment in laboratory models.
The players
NSUN5
This is a protein identified as a therapeutic target that contributes to drug resistance in cancer cells.
Fibronectin 1
This protein-coding gene produces transcripts that are stabilized by NSUN5 to promote tumor growth.
The details
NSUN5 enables the stabilization of Fibronectin 1 mRNA, which subsequently activates the oncogenic PI3K/AKT signaling pathway. Researchers successfully identified a small-molecular inhibitor that disrupts this process, effectively slowing tumor growth in patient-derived xenografts.
Timeline
September 30, 2026: Article published online
The Big Picture
This discovery shifts the understanding of resistance by identifying a regulatory step that modulates the activity of the PI3K/AKT signaling pathway. It marks a departure from traditional drug-target identification by focusing on mRNA modification mechanisms.
This research provides a new potential therapeutic target that could eventually improve treatment options for those facing drug-resistant kidney cancer. Patients should consult with their oncologists to understand how evolving research might influence future care strategies.
The takeaway
Targeting specific mRNA modifiers may be a highly effective way to overcome treatment resistance in oncology. Future research will focus on translating these laboratory successes into clinical applications for cancer patients.
Further reading
For more information on the latest research in this field, visit the Cancer section.
Source note: This article includes information reported by Nature.
